Q-omics provides the consensus-scored SNORD121A profile across patient tissues and cancer cell-line models. SNORD121A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SNORD121A is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, SNORD121A RNA expression shows 9,341 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, BLCA, and TGCT as cancer lineages where SNORD121A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD121A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD121A survival associations across molecular data types. SNORD121A RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD121A RNA expression–survival associations across cancer types. High SNORD121A expression shows unfavorable associations in LIHC, SKCM, MESO, THCA and UVM, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify OV as the clearest survival context for SNORD121A RNA expression.
This table summarizes SNORD121A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD121A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD121A shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LUAD, STAD and LUSC. The BLCA box plot shows higher SNORD121A RNA expression in tumor versus normal tissue (log2 FC = +0.657, t-test p = .002).
This table shows molecular features associated with SNORD121A in patient tissues and cancer cell lines. In patient samples, SNORD121A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
